Emitefur

structure given in first source

Also Known As:

3 (3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil; BOF A2; BOF-A2; Benzoic acid, 3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester

Networked: 22 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - Uracil: 1493
        Fluorouracil: 26711
        Emitefur: 22

Experts

1.	Eng, C: 1 article (08/2001)
2.	Kindler, H L: 1 article (08/2001)
3.	Schilsky, R L: 1 article (08/2001)
4.	Corey, A: 1 article (10/2000)
5.	Eager, R: 1 article (10/2000)
6.	Hoff, P M: 1 article (10/2000)
7.	Nemunaitis, J: 1 article (10/2000)
8.	Pazdur, R: 1 article (10/2000)
9.	Sekar, K: 1 article (10/2000)
10.	Thompson, J: 1 article (10/2000)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 01/01/2000 - "Based on the above findings, BOF-A2 is considered to be a promising anticancer drug for patients with advanced gastric cancer." 08/01/1994 - "The combination therapy of BOF-A2 with CDDP was effective against stomach cancer (H-111) from the cellular change and decreased side effect. " 08/01/1994 - "The combination therapy of BOF-A2 with MMC showed additive effect against stomach cancer (H-111) from IR and cellular changes. " 01/01/2000 - "A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer." 01/01/2000 - "The antineoplastic effects of BOF-A2 (Emitefur), a 5-fluorouracil (5-FU) derivative, in capsule form were assessed in patients with advanced gastric cancer, in a multicenter late phase II study and at 11 different hospitals. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/1994 - "Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. " 01/01/1994 - "Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation, was administered to 71 non-small cell lung cancer (NSCLC) patients in a multi-center phase II study. "
3.	Colorectal Neoplasms (Colorectal Cancer) 07/01/1994 - "We investigated the effects of BOF-A2 on the metastasis of colorectal cancer using artificial (experimental) and spontaneous metastasis of Colon 26 tumor cells. " 08/01/2001 - "The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer."
4.	Neoplasms (Cancer) 10/01/2000 - "To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors. " 10/01/2000 - "Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors." 08/01/1994 - "BOF-A2 was expected to be a promising new anti-cancer agent in the future clinical trial." 02/01/1993 - "Antitumor effects of BOF-A2 given intermittently was evaluated with human gastric (H-111, H-83), colorectal (H-110, H-143) and lung (H-74, LC-376) cancers xenografted in nude mice and compared with those by continuous administration. " 09/01/1990 - "Twenty-five consecutive oral administration of BOF-A2 at 17.5 to 30 mg/kg over 4 weeks caused marked inhibition or regression (over 92% of inhibition rate) to the growth of H-81, H-143 and H-31 cancers. "
5.	Yoshida Sarcoma 02/01/1989 - "The ED50 (the dose for 50% inhibition) values of BOF-A2 were 25 mg/kg against sarcoma-180 and 15 mg/kg against Yoshida sarcoma. " 02/01/1989 - "The antitumor activity of BOF-A2 was investigated in sarcoma-180-bearing mice and Yoshida sarcoma-bearing rats. " 07/01/1987 - "BOF-A1 and BOF-A2, new compounds combined with CNDP were markedly active against mouse sarcoma 180 and rat Yoshida sarcoma." 02/01/1989 - "After oral administration of BOF-A2 at 15 mg/kg to Yoshida sarcoma-bearing rats, BOF-A2 was hydrolyzed to EM-FU, CNDP and 5-FU, and their maximum concentrations in the blood were 2000 ng/ml, 300 ng/ml and 40 ng/ml, respectively. "

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Uracil
3.	Tegafur
4.	Prodrugs
5.	Leucovorin (Folinic Acid)
6.	Capecitabine (Xeloda)
7.	Emitefur
8.	Antineoplastic Agents (Antineoplastics)
9.	Capsules (Microcapsules)
10.	2,6-dihydroxy-3-cyanopyridine

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Adjuvant Chemotherapy
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Drug Therapy (Chemotherapy)